- Conditions
- Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer, Lung Cancer, MMR-deficient Tumors, Breast Cancer, Pancreatic Cancer, Renal Cell Carcinoma (RCC), Solid Tumors, UC (Urothelial Cancer)
- Interventions
- Pembrolizumab, itacitinib, INCB050465
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Trismus
- Interventions
- Dynasplint Trismus System, Tongue Depressors
- Device · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- ASC-US, ASC-H, LSIL
- Interventions
- PVX-2, Placebo
- Biological · Other
- Lead sponsor
- PapiVax Biotech, Inc.
- Other
- Eligibility
- 25 Years to 70 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
- Conditions
- Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cancer of Head and Neck
- Interventions
- LY2523355, pegfilgrastim
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 18
- States / cities
- Jonesboro, Arkansas • Jacksonville, Florida • Macon, Georgia + 15 more
- Conditions
- Pleuropulmonary Blastoma, Cystic Nephroma, Ovarian Sertoli-Leydig Cell Tumors, Ocular Medulloepithelioma, Nasal Chondromesenchymal Hamartoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Month to 99 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2011
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Rockville, Maryland
- Conditions
- Cancer of the Larynx
- Interventions
- Intensity modulated radiation therapy
- Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Foundation for the National Institutes of Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Minneapolis, Minnesota • Salt Lake City, Utah
- Conditions
- Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, Cancer Colorectal, Cancer, Endometrial, Cancer of Head and Neck, Non Small Cell Lung Cancer, CVD - Cardiovascular Disease, Diabetes Mellitus, Hypercholesterolemia, Diabetes, Cancer of Esophagus, Cancer of Liver, Cancer, Renal Cell, Cancer of Pancreas, Cancer Ovaries
- Interventions
- iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Resectable Head and Neck Squamous Cell Carcinoma
- Interventions
- 42 Gy Radiation Therapy, 39 Gy Radiation Therapy, 32.5 Gy Radiation Therapy
- Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- BYL719 as film-coated (FC) whole tablets, BYL719 as dispersible tablets (DT), cetuximab, BYL719 drink suspension
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 14
- States / cities
- Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- Cancer of Head and Neck, Smoking
- Interventions
- Not listed
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Cervical Cancer, Papilloma Viral Infection
- Interventions
- Stage 1 SOC, Stage 1 HERS, Stage 2 HERS, Stage 2 HERS+HC, Stage 3 SOC, Stage 3 HERS, Stage 3 HERS+HC, Stage 4 HERS, Stage 4 HERS+HC
- Behavioral
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 546 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Precancerous Condition
- Interventions
- vandetanib, placebo, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, pharmacological study
- Drug · Other · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Anxiety Disorder, Depression, Fatigue, Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pain, Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Gestational Trophoblastic Tumor, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
- Interventions
- questionnaire administration, quality-of-life assessment, psychosocial assessment and care, behavioral intervention, cognitive intervention, educational intervention
- Other · Procedure · Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years to 85 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
- Interventions
- Audio + Radio (AURA)
- Behavioral
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • San Antonio, Texas
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
- Interventions
- ixabepilone, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Interventions
- MT-6402
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more
- Conditions
- Thyroid Cancer
- Interventions
- Avutometinib, Defactinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Cervix Carcinoma
- Interventions
- Proflavine, High-Resolution Microendoscopy (HRME) Imaging
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 21 Years to 64 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Oral Cavity Neoplasm
- Interventions
- High-Resolution Microendoscopy, Multispectral Imaging, Proflavine
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cervical Cancer
- Interventions
- Discussion & scoring of health states related to the treatment of cervical cancer
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cancer, Breast Cancer, Brain Cancer, Central Nervous System Cancer, Colorectal Cancer, Esophageal Cancer, Gynecologic Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Melanoma, Blood Cancer, Lung Cancer, Acceptance and Commitment Therapy, Mind-Body Therapies, Psychosocial Intervention
- Interventions
- Mind Over Matter (MOM)
- Other
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Fairfax, Virginia
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- Pamiparib, Temozolomide
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Grand Rapids, Michigan • St Louis, Missouri • New York, New York + 4 more
- Conditions
- Cervical Dysplasia
- Interventions
- Nelfinavir
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas